



# Biotech Daily

Friday November 15, 2013

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: PRIMA UP 14%, MEDICAL DEVELOPMENTS DOWN 6%**
- \* **CALZADA LOSES CHAIR DAVID FRANKLYN AT AGM, DR ROGER ASTON IN**
- \* **PRIMA LOSES REVIVER MARTIN ROGERS**
- \* **CIRCADIAN EXPECTS \$2.5m FEDERAL R&D TAX REFUND**
- \* **CONSEGNA BECOMES RHINOMED ON MONDAY**
- \* **UBS AG REDUCES TO 5% OF NEUREN**

## MARKET REPORT

The Australian stock market climbed 0.86 percent on Friday November 15, 2013 with the S&P ASX 200 up 46.3 points to 5,401.7 points.

Twenty of the Biotech Daily Top 40 stocks were up, 14 fell, five traded unchanged and one was untraded. All three Big Caps were up.

Prima was the best, up half a cent or 14.3 percent to four cents with 14.0 million shares traded, followed by Compumedics up 13.75 percent to 9.1 cents with 227,977 shares traded, Neuren up 13.6 percent to 12.5 cents with 28.7 million shares traded and Atcor up 10.5 percent to 21 cents with 2.1 million shares traded.

Cellmid climbed 7.7 percent; GI Dynamics was up 6.5 percent; Prana rose 5.7 percent; Anteo, Avita and Circadian were up more than four percent; Ellex, Patrys and Starpharma were up more than three percent; Allied Health and Living Cell rose more than two percent; Cochlear, Genetic Technologies, Osprey and Resmed were up more than one percent; with Benitec, CSL, Psivida and Sirtex up by less than one percent.

Medical Developments led the falls, down eight cents or 5.9 percent to \$1.28 with 17,000 shares traded, followed by Phylogica down 5.3 percent to 1.8 cents with 100,000 shares traded.

Pharmaxis fell 4.2 percent; IDT and QRX lost more than three percent; Alchemia, Mesoblast, Tissue Therapies and Viralytics shed more than two percent; Bionomics, Clinuvel, Impedimed and Nanosonics were down more than one percent; with Reva down 0.85 percent.

## CALZADA

Calzada says the annual general meeting resolution to re-elect chairman David Franklyn was withdrawn before the vote was held.

Mr Franklyn was not available to comment.

Mr Franklyn was appointed chairman in 2009 and had acted as executive chairman.

Mr Franklyn's chairman's address referred to plans to reform the company and clarify the relationship with Metabolic including "review its ongoing commitment to the Metabolic business, including whether it may be separated as an entity in its own right".

Calzada has concentrated on the development of subsidiary Polynovo's Novosorb for a range of treatments (BD: Mar 28, Jul 9, 17, 26, Oct 10, 2013)

Metabolic is the owner of the failed and controversial anti-obesity drug AOD9604 at the centre of the Essendon Football Club scandal throughout 2013 (BD: Jul 29, 2013).

Calzada said that Dr Roger Aston had agreed to join the board as a director.

Dr Aston is chair of Immuron and Pharmaust and a director of IDT, Immuron, Oncosil and Regeneus.

The company said that the adoption of the remuneration report was opposed by 16,616,050 votes (10.5%) with 141,196,945 votes (89.5%) in favor, while the ratification of a prior share issue was opposed by 18,292,925 votes (13.3%) with 119,601,079 votes (86.7%) in favor.

The company's most recent Appendix 3B new issue announcement said that Calzada had 416,318,870 shares on issue, meaning that the votes against the share issue amounted to 4.4 percent of the company, not sufficient to requisition extraordinary general meetings. Calzada was up 0.3 cents or 4.1 percent to 7.6 cents.

## PRIMA BIOMED

Prima says the resolution to re-elect former chief executive officer and director Martin Rogers was withdrawn prior to the annual general meeting.

Mr Rogers joined Prima as an executive director in 2007 and has been credited with taking the company for its low of half a cent a share to a high of 42 cents a share.

Mr Rogers told Biotech Daily that he retired from the company having made a contribution, believing that the lead technology CVac for ovarian cancer worked and he had other projects on which he wanted to focus.

"I think my job is done," Mr Rogers said.

Mr Rogers continues as chairman of Oncosil (formerly Neurodiscovery) and Conseгна (to be renamed Rhinomed) and as a director of Cellmid.

Prima said that 13,499,268 proxy votes (15%) were recorded against the re-election of Mr Rogers with 76,589,072 votes (85%) in favor.

Mr Rogers told Biotech Daily that although the resolution was not put, the 72,157,815 proxy votes held at the chair's discretion would have been in his favor.

Prima said the remuneration report was opposed by 10,322,556 shares (7.8%) and passed with 122,255,119 shares (92.2%) in favor.

Chair Lucy Turnbull was re-elected with 6,221,896 votes (6.9%) against and 83,985,151 votes (93.1%) in favor with Dr Russell Howard re-elected with more than 87.9 million votes in favor and 2,185,029 votes against.

The company's most recent Appendix 3B new issue announcement said that Prima had 1,228,709,341 shares on issue, meaning that the votes against Mr Rogers amounted to 1.1 percent of the company, not sufficient to requisition extraordinary general meetings. Prima was up half a cent or 14.3 percent to four cents with 14.0 million shares traded.

### CIRCADIAN TECHNOLOGIES

Circadian says it expects to receive \$2.5 million from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Circadian said the rebate included \$600,000 relating to offshore research and development expenditure for the year to June 30, 2013 as well as activities for the years to June 30, 2014 and June 30, 2015.

The company said it expected to invest about \$7.5 million in research and development in support of its oncology and eye disease programs and expected to receive about \$3.0 million in refundable tax credit for the year to June 30, 2014.

Circadian was up one cent or 4.2 percent to 25 cents.

### CONSEGNA GROUP

Consegna says it has officially completed its name change to Rhinomed and will trade under the ASX ticker code RNO from Monday November 18, 2013.

Consegna chief executive officer Michael Johnson said Rhinomed “reflects our goal of developing and commercializing technologies that will significantly improve the way people breathe”.

Mr Johnson said the company would start shipping its first product, the Turbine for sport and exercise from November 20, 2013.

Consegna said the company was “developing technologies that focus on the role the nose plays in breathing and maintaining and improving health and wellbeing”.

Consegna was up 0.4 cents or 6.8 percent to 6.3 cents with 1.3 million shares traded.

### NEUREN PHARMACEUTICALS

UBS AG and related companies have reduced their substantial shareholding in Neuren from 90,539,390 shares (6.24%) to 76,928,129 shares (5.23%).

Last month, UBS AG and related companies became substantial shareholders in Neuren with 90,539,390 shares or 6.24 percent of the company (BD: Oct 31, 2013).

Today, the UBS substantial shareholder notice filed from Singapore said that UBS Securities Australia was the beneficial owner of 14,894,647 shares (1.01%) and UBS AG, Australia Branch had an interest in 62,033,482 shares (4.22%) held as “borrowing right in respect of shares pursuant to a prime broking agreement”, with UBS AG London Branch holding 869,565 shares (0.06%) also as a “borrowing right”.

UBS said it bought and sold shares, mainly in small parcels from October 29, to November 12, 2013, with the single largest sale on October 31 of 4,000,000 shares for \$460,000 or 11.5 cents a share, the same price as the \$21.5 million placement (BD: Oct 22, 2013).

Neuren was up 1.5 cents or 13.6 percent to 12.5 cents with 28.7 million shares traded.